Trial Profile

Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; Selumetinib (Primary) ; Capecitabine
Indications Adenocarcinoma; Rectal cancer
Focus Adverse reactions
Acronyms DREAM; DREAMtherapy

Most Recent Events

20 Jun 2019 Results published in the European Journal of Cancer
26 Jan 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
09 Feb 2015 Planned End Date changed from 1 Dec 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com